NS Healthcare is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
White Paper
December 13, 2018
Alzheimer’s disease is the most common cause of dementia, which currently affects over 46.8 million people across the world today. The ApoE4 varient of apoliprotein E (ApoE) is recognised at one of the most prominent genetic risk factors for dementia due to its implication with Alzheimer’s contributing factors, and is now screened for by the medical industry. Randox Laboratories has produced its Biochip Arrow Technology (BAT) platform to allow the direct identification of ApoE4 through simultaneous chemiluminescent sandwich immunoassays, which can also be performed by the company’s Evidence series of biochip analysers.
Download to find out more.